Endometrium adenocarcinoma
MONDO:0005461An adenocarcinoma arising from the uterine body cavity. This is the most frequent malignant tumor affecting the uterine body, and is linked to estrogen therapy. Most patients present with uterine bleeding and are over age 40 at the time of diagnosis. The prognosis depends on the stage of the tumor, the depth of the uterine wall invasion, and the histologic subtype. Endometrioid adenocarcinoma is the most frequently seen morphologic variant of endometrial adenocarcinoma.
Also known as: endometrioid carcinoma of endometrium, adenocarcinoma of endometrium, adenocarcinoma of the endometrium, adenocarcinoma, endometrial, malignant, endometrial adenocarcinoma, endometrioid adenoma or carcinoma NOS (morphologic abnormality), endometrioid adenomas and carcinomas (morphologic abnormality), endometrium adenocarcinoma
2964 clinical trials for this condition and its sub-types, 30 tagged with Endometrium adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Endometrium adenocarcinoma
-
Ovarian endometrioid adenocarcinoma 78 trials
1 sub-type
-
Endometrial clear cell adenocarcinoma 21 trials
-
Endometrial mixed adenocarcinoma 10 trials
-
Endometrial mucinous adenocarcinoma 2 trials
-
New drug cocktail targets Hard-to-Treat ovarian and endometrial cancers
Disease control CompletedThis early-stage trial tested two drugs—niraparib and copanlisib—in 31 people with recurrent endometrial, ovarian, peritoneal, or fallopian tube cancer. The goal was to find the safest dose and see how well patients tolerated the combination. Both drugs work by blocking enzymes t…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Hormone blockers join forces against Treatment-Resistant endometrial cancer
Disease control CompletedThis phase II trial tests whether combining two hormone-blocking drugs — onapristone and anastrozole — can shrink tumors or slow cancer growth in women with hormone-receptor-positive endometrial cancer that has not responded to prior chemotherapy. Onapristone blocks progesterone …
Phase 2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug cocktail shows promise for Hormone-Sensitive uterine cancer
Disease control CompletedThis phase 2 study tested a combination of two drugs, fulvestrant and abemaciclib, in 28 patients with a specific type of uterine cancer that is sensitive to hormones. The goal was to see if the drugs could shrink tumors or stop them from growing. Researchers also tracked side ef…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Shorter radiation after hysterectomy shows promise for endometrial cancer
Disease control CompletedThis study tested a shorter course of pelvic radiation (about 1 week instead of the usual 5-6 weeks) given after hysterectomy for advanced endometrial cancer. The goal was to see if this shorter treatment causes fewer side effects while still controlling the cancer. The study inc…
Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Chemo's hidden toll: study probes life after endometrial cancer treatment
Knowledge-focused CompletedThis study looked at how chemotherapy impacts the quality of life of women treated for stage II or III endometrial cancer. Researchers asked 51 patients to fill out questionnaires about their physical, emotional, and social well-being at least two years after finishing treatment.…
Sponsor: Centre Francois Baclesse • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Blood mineral levels may differ in women's reproductive diseases
Knowledge-focused CompletedThis study measured 14 trace elements in blood samples from 40 women with endometriosis, ovarian cancer, endometrial cancer, or healthy controls. Researchers wanted to see if levels of elements like iron, selenium, or lead differ between these groups. The goal is to find clues th…
Sponsor: Cumhuriyet University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Universal DNA screening in endometrial cancer reveals hidden genetic risks
Knowledge-focused CompletedThis study tested over 1,000 women with endometrial cancer for DNA repair problems that can be inherited (Lynch syndrome). By analyzing tumor DNA, researchers aimed to personalize cancer treatment and identify family members who might also be at risk. The goal was to improve care…
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC